

SAMPLE DIRECT IMMUNOFLUORESCENCE REPORT

DIAGNOSIS:

ABC Hospital SU07-12345

Skin, left inner upper thigh, biopsy: **Positive** direct immunofluorescence studies, consistent with bullous pemphigoid (please see comments).

COMMENTS:

Linear deposits of IgG and C3 along the dermal-epidermal junction are characteristic of bullous pemphigoid (BP). It should be noted, however, that these findings are not entirely specific for BP, as similar findings can be found in epidermolysis bullosa acquisita (EBA). If clinically warranted, additional studies can be performed to distinguish between BP and EBA based on the localization of the immunoglobulin deposits.

SPECIMEN INFORMATION:

A1 = SU07-12345, 1 wet specimen

RECEIVED FOR THE FOLLOWING:


Direct immunofluorescence studies to rule out bullous pemphigoid vs other bullous dermatosis.

GROSS DESCRIPTION:

Received in Michel's transport media (pH = 7.30) from ABC Hospital (Dr. Joseph Smith) is a single punch biopsy of skin measuring 4 x 4 x 5 mm.

IMMUNOFLUORESCENCE FINDINGS:

The specimen is washed, embedded in OCT media, and snap-frozen in liquid nitrogen cooled isopentane. Frozen sections are cut and incubated with a panel of FITC-conjugated antibodies and localized via direct fluorescence. Positive and negative control slides are reviewed for each test and found to be satisfactory. Results are as indicated in the table below.



Block SU07-12345 (Surgery Date: 06/25/2007) - Skin, left inner upper thigh, biopsy (PP2007XXXXX A1)

Antibodies To	Result
Complement (C3)	3+ linear along the dermal-epidermal junction
IgA	Negative
IgG	3+ linear along the dermal-epidermal junction
IgM	Negative

*****ELECTRONICALLY SIGNED***** **Allen M. Gown, M.D., Medical Director & Chief Pathologist**

Per CMS regulations, the pathologist's signature above indicates that this case has been reviewed and the diagnosis made or confirmed by said Pathologist.

NOTE: Some of the tests reported here may have been developed and performance characteristics determined by PhenoPath Laboratories. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). However, the FDA has determined that such clearance or approval is not necessary. Pursuant to the requirements of CLIA, this laboratory has established and verified the accuracy and precision of all tests, and additional information about these tests is available upon request. PhenoPath Laboratories is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.